Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac – PROFISCOV: A structured summary of a study protocol for a randomised controlled trial
Objectives To evaluate the efficacy of two doses of the adsorbed vaccine COVID-19 (inactivated) produced by Sinovac in symptomatic individuals, with virological confirmation of COVID-19, two weeks after the completion of the two-dose vaccination regimen, aged 18 years or older who work as health pro...
Saved in:
| Published in: | Current controlled trials in cardiovascular medicine Vol. 21; no. 1; pp. 853 - 3 |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
London
BioMed Central
15.10.2020
Springer Nature B.V BMC |
| Subjects: | |
| ISSN: | 1745-6215, 1745-6215 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Objectives
To evaluate the efficacy of two doses of the adsorbed vaccine COVID-19 (inactivated) produced by Sinovac in symptomatic individuals, with virological confirmation of COVID-19, two weeks after the completion of the two-dose vaccination regimen, aged 18 years or older who work as health professionals providing care to patients with possible or confirmed COVID-19.
To describe the occurrence of adverse reactions associated with the administration of each of two doses of the adsorbed vaccine COVID-19 (inactivated) produced by Sinovac up to one week after vaccination in Adults (18-59 years of age) and Elderly (60 years of age or more).
Trial design
This is a Phase III, randomized, multicenter, endpoint driven, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of the adsorbed vaccine COVID-19 (inactivated) produced by Sinovac.
The adsorbed vaccine COVID-19 (inactivated) produced by Sinovac (product under investigation) will be compared to placebo. Voluntary participants will be randomized to receive two intramuscular doses of the investigational product or the placebo, in a 1: 1 ratio, stratified by age group (18 to 59 years and 60 years or more) and will be monitored for one year by active surveillance of COVID-19. Two databases will be established according to the age groups: one for adults (18-59 years) and one for the elderly (60 years of age or older).
The threshold to consider the vaccine efficacious will be to reach a protection level of at least 50%, as proposed by the World Health Organization and the FDA. Success in this criterion will be defined by sequential monitoring with adjustment of the lower limit of the 95% confidence interval above 30% for the primary efficacy endpoint.
Participants
Healthy participants and / or participants with clinically controlled disease, of both genders, 18 years of age or older, working as health professionals performing care in units specialized in direct contact with people with possible or confirmed cases of COVID-19. Participation of pregnant women and those who are breastfeeding, as well as those intending to become pregnant within three months after vaccination will not be allowed. Participants will only be included after signing the voluntary Informed Consent Form and ensuring they undergo screening evaluation and conform to all the inclusion and exclusion criteria. All the clinical sites are located in Brazil.
Intervention and comparator
Experimental intervention: The vaccine was manufactured by Sinovac Life Sciences (Beijing, China) and contains 3 μg/0.5 mL (equivalent to 600 SU per dose) of inactivated SARS-CoV-2 virus, and aluminium hydroxide as adjuvant.
Control comparator: The placebo contains aluminium hydroxide in a 0.5 mL solution
The schedule of both, experimental intervention and placebo is two 0.5 mL doses IM (deltoid) with a two week interval.
Main outcomes
The primary efficacy endpoint is the incidence of symptomatic cases of virologically confirmed COVID-19 two weeks after the second vaccination. The virological diagnosis will be confirmed by detection of SARS-CoV-2 nucleic acid in a clinical sample.
The primary safety endpoint is the frequency of solicited and unsolicited local and systemic adverse reactions during the period of one week after vaccination according to age group in adult (18-59 years old) and elder (60 years of age or older) subjects. Adverse reactions are defined as adverse events that have a reasonable causal relationship to vaccination.
Randomisation
There will be two randomization lists, one for each age group, based on the investigational products to be administered,
i.e
., vaccine or placebo at a 1: 1 ratio. Each randomization list will be made to include up to 11,800 (18-59 year-old) adults, and 1,260 elderly (60 y-o and older) participants, the maximum number of participants needed per age group. An electronic central randomization system will be used to designate the investigational product that each participant must receive.
Blinding (masking)
This trial is designed as a double-blind study to avoid introducing bias in the evaluation of efficacy, safety and immunogenicity. The clinical care team, the professionals responsible for the vaccination and the participants will not know which investigational product will be administered. Only pharmacists or nurses in the study who are responsible for the randomization, separation and blinding of the investigational product will have access to unblinded information. The sponsor's operational team will also remain blind.
Numbers to be randomised (sample size)
The total number of participants needed to evaluate efficacy, 13,060 participants, satisfies the needed sample size calculated to evaluate safety. Therefore, the total number obtained for efficacy will be the number retained for the study. Up to 13,060 participants are expected to enter the study, with up to 11,800 participants aged 18 to 59 years and 1,260 elderly participants aged 60 and over. Half of the participants of each group will receive the experimental vaccine and half of them will receive the placebo. The recruitment of participants may be modified as recommended by the Data Safety Monitoring Committee at time of the interim unblinded analysis or blind assessment of the COVID-19 attack rate during the study.
Trial Status
Protocol version 2.0 – 24-Aug-2020. Recruitment started on July 21
st
, 2020. The recruitment is expected to conclude in October 2020.
Trial registration
ClinicalTrials.gov Identifier:
NCT0445659
. Registry on 2 July 2020
Full protocol
The full protocol is attached as an additional file, accessible from the Trials website (Additional file
1
). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. |
|---|---|
| AbstractList | To evaluate the efficacy of two doses of the adsorbed vaccine COVID-19 (inactivated) produced by Sinovac in symptomatic individuals, with virological confirmation of COVID-19, two weeks after the completion of the two-dose vaccination regimen, aged 18 years or older who work as health professionals providing care to patients with possible or confirmed COVID-19. To describe the occurrence of adverse reactions associated with the administration of each of two doses of the adsorbed vaccine COVID-19 (inactivated) produced by Sinovac up to one week after vaccination in Adults (18-59 years of age) and Elderly (60 years of age or more).
This is a Phase III, randomized, multicenter, endpoint driven, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of the adsorbed vaccine COVID-19 (inactivated) produced by Sinovac. The adsorbed vaccine COVID-19 (inactivated) produced by Sinovac (product under investigation) will be compared to placebo. Voluntary participants will be randomized to receive two intramuscular doses of the investigational product or the placebo, in a 1: 1 ratio, stratified by age group (18 to 59 years and 60 years or more) and will be monitored for one year by active surveillance of COVID-19. Two databases will be established according to the age groups: one for adults (18-59 years) and one for the elderly (60 years of age or older). The threshold to consider the vaccine efficacious will be to reach a protection level of at least 50%, as proposed by the World Health Organization and the FDA. Success in this criterion will be defined by sequential monitoring with adjustment of the lower limit of the 95% confidence interval above 30% for the primary efficacy endpoint.
Healthy participants and / or participants with clinically controlled disease, of both genders, 18 years of age or older, working as health professionals performing care in units specialized in direct contact with people with possible or confirmed cases of COVID-19. Participation of pregnant women and those who are breastfeeding, as well as those intending to become pregnant within three months after vaccination will not be allowed. Participants will only be included after signing the voluntary Informed Consent Form and ensuring they undergo screening evaluation and conform to all the inclusion and exclusion criteria. All the clinical sites are located in Brazil.
Experimental intervention: The vaccine was manufactured by Sinovac Life Sciences (Beijing, China) and contains 3 μg/0.5 mL (equivalent to 600 SU per dose) of inactivated SARS-CoV-2 virus, and aluminium hydroxide as adjuvant. Control comparator: The placebo contains aluminium hydroxide in a 0.5 mL solution The schedule of both, experimental intervention and placebo is two 0.5 mL doses IM (deltoid) with a two week interval.
The primary efficacy endpoint is the incidence of symptomatic cases of virologically confirmed COVID-19 two weeks after the second vaccination. The virological diagnosis will be confirmed by detection of SARS-CoV-2 nucleic acid in a clinical sample. The primary safety endpoint is the frequency of solicited and unsolicited local and systemic adverse reactions during the period of one week after vaccination according to age group in adult (18-59 years old) and elder (60 years of age or older) subjects. Adverse reactions are defined as adverse events that have a reasonable causal relationship to vaccination.
There will be two randomization lists, one for each age group, based on the investigational products to be administered, i.e., vaccine or placebo at a 1: 1 ratio. Each randomization list will be made to include up to 11,800 (18-59 year-old) adults, and 1,260 elderly (60 y-o and older) participants, the maximum number of participants needed per age group. An electronic central randomization system will be used to designate the investigational product that each participant must receive.
This trial is designed as a double-blind study to avoid introducing bias in the evaluation of efficacy, safety and immunogenicity. The clinical care team, the professionals responsible for the vaccination and the participants will not know which investigational product will be administered. Only pharmacists or nurses in the study who are responsible for the randomization, separation and blinding of the investigational product will have access to unblinded information. The sponsor's operational team will also remain blind.
The total number of participants needed to evaluate efficacy, 13,060 participants, satisfies the needed sample size calculated to evaluate safety. Therefore, the total number obtained for efficacy will be the number retained for the study. Up to 13,060 participants are expected to enter the study, with up to 11,800 participants aged 18 to 59 years and 1,260 elderly participants aged 60 and over. Half of the participants of each group will receive the experimental vaccine and half of them will receive the placebo. The recruitment of participants may be modified as recommended by the Data Safety Monitoring Committee at time of the interim unblinded analysis or blind assessment of the COVID-19 attack rate during the study.
Protocol version 2.0 - 24-Aug-2020. Recruitment started on July 21
, 2020. The recruitment is expected to conclude in October 2020.
ClinicalTrials.gov Identifier: NCT0445659 . Registry on 2 July 2020 FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. ObjectivesTo evaluate the efficacy of two doses of the adsorbed vaccine COVID-19 (inactivated) produced by Sinovac in symptomatic individuals, with virological confirmation of COVID-19, two weeks after the completion of the two-dose vaccination regimen, aged 18 years or older who work as health professionals providing care to patients with possible or confirmed COVID-19.To describe the occurrence of adverse reactions associated with the administration of each of two doses of the adsorbed vaccine COVID-19 (inactivated) produced by Sinovac up to one week after vaccination in Adults (18-59 years of age) and Elderly (60 years of age or more).Trial designThis is a Phase III, randomized, multicenter, endpoint driven, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of the adsorbed vaccine COVID-19 (inactivated) produced by Sinovac.The adsorbed vaccine COVID-19 (inactivated) produced by Sinovac (product under investigation) will be compared to placebo. Voluntary participants will be randomized to receive two intramuscular doses of the investigational product or the placebo, in a 1: 1 ratio, stratified by age group (18 to 59 years and 60 years or more) and will be monitored for one year by active surveillance of COVID-19. Two databases will be established according to the age groups: one for adults (18-59 years) and one for the elderly (60 years of age or older).The threshold to consider the vaccine efficacious will be to reach a protection level of at least 50%, as proposed by the World Health Organization and the FDA. Success in this criterion will be defined by sequential monitoring with adjustment of the lower limit of the 95% confidence interval above 30% for the primary efficacy endpoint.ParticipantsHealthy participants and / or participants with clinically controlled disease, of both genders, 18 years of age or older, working as health professionals performing care in units specialized in direct contact with people with possible or confirmed cases of COVID-19. Participation of pregnant women and those who are breastfeeding, as well as those intending to become pregnant within three months after vaccination will not be allowed. Participants will only be included after signing the voluntary Informed Consent Form and ensuring they undergo screening evaluation and conform to all the inclusion and exclusion criteria. All the clinical sites are located in Brazil.Intervention and comparatorExperimental intervention: The vaccine was manufactured by Sinovac Life Sciences (Beijing, China) and contains 3 μg/0.5 mL (equivalent to 600 SU per dose) of inactivated SARS-CoV-2 virus, and aluminium hydroxide as adjuvant.Control comparator: The placebo contains aluminium hydroxide in a 0.5 mL solutionThe schedule of both, experimental intervention and placebo is two 0.5 mL doses IM (deltoid) with a two week interval.Main outcomesThe primary efficacy endpoint is the incidence of symptomatic cases of virologically confirmed COVID-19 two weeks after the second vaccination. The virological diagnosis will be confirmed by detection of SARS-CoV-2 nucleic acid in a clinical sample.The primary safety endpoint is the frequency of solicited and unsolicited local and systemic adverse reactions during the period of one week after vaccination according to age group in adult (18-59 years old) and elder (60 years of age or older) subjects. Adverse reactions are defined as adverse events that have a reasonable causal relationship to vaccination.RandomisationThere will be two randomization lists, one for each age group, based on the investigational products to be administered, i.e., vaccine or placebo at a 1: 1 ratio. Each randomization list will be made to include up to 11,800 (18-59 year-old) adults, and 1,260 elderly (60 y-o and older) participants, the maximum number of participants needed per age group. An electronic central randomization system will be used to designate the investigational product that each participant must receive.Blinding (masking)This trial is designed as a double-blind study to avoid introducing bias in the evaluation of efficacy, safety and immunogenicity. The clinical care team, the professionals responsible for the vaccination and the participants will not know which investigational product will be administered. Only pharmacists or nurses in the study who are responsible for the randomization, separation and blinding of the investigational product will have access to unblinded information. The sponsor's operational team will also remain blind.Numbers to be randomised (sample size)The total number of participants needed to evaluate efficacy, 13,060 participants, satisfies the needed sample size calculated to evaluate safety. Therefore, the total number obtained for efficacy will be the number retained for the study. Up to 13,060 participants are expected to enter the study, with up to 11,800 participants aged 18 to 59 years and 1,260 elderly participants aged 60 and over. Half of the participants of each group will receive the experimental vaccine and half of them will receive the placebo. The recruitment of participants may be modified as recommended by the Data Safety Monitoring Committee at time of the interim unblinded analysis or blind assessment of the COVID-19 attack rate during the study.Trial StatusProtocol version 2.0 – 24-Aug-2020. Recruitment started on July 21st, 2020. The recruitment is expected to conclude in October 2020.Trial registrationClinicalTrials.gov Identifier: NCT0445659. Registry on 2 July 2020Full protocolThe full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. To evaluate the efficacy of two doses of the adsorbed vaccine COVID-19 (inactivated) produced by Sinovac in symptomatic individuals, with virological confirmation of COVID-19, two weeks after the completion of the two-dose vaccination regimen, aged 18 years or older who work as health professionals providing care to patients with possible or confirmed COVID-19. To describe the occurrence of adverse reactions associated with the administration of each of two doses of the adsorbed vaccine COVID-19 (inactivated) produced by Sinovac up to one week after vaccination in Adults (18-59 years of age) and Elderly (60 years of age or more).OBJECTIVESTo evaluate the efficacy of two doses of the adsorbed vaccine COVID-19 (inactivated) produced by Sinovac in symptomatic individuals, with virological confirmation of COVID-19, two weeks after the completion of the two-dose vaccination regimen, aged 18 years or older who work as health professionals providing care to patients with possible or confirmed COVID-19. To describe the occurrence of adverse reactions associated with the administration of each of two doses of the adsorbed vaccine COVID-19 (inactivated) produced by Sinovac up to one week after vaccination in Adults (18-59 years of age) and Elderly (60 years of age or more).This is a Phase III, randomized, multicenter, endpoint driven, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of the adsorbed vaccine COVID-19 (inactivated) produced by Sinovac. The adsorbed vaccine COVID-19 (inactivated) produced by Sinovac (product under investigation) will be compared to placebo. Voluntary participants will be randomized to receive two intramuscular doses of the investigational product or the placebo, in a 1: 1 ratio, stratified by age group (18 to 59 years and 60 years or more) and will be monitored for one year by active surveillance of COVID-19. Two databases will be established according to the age groups: one for adults (18-59 years) and one for the elderly (60 years of age or older). The threshold to consider the vaccine efficacious will be to reach a protection level of at least 50%, as proposed by the World Health Organization and the FDA. Success in this criterion will be defined by sequential monitoring with adjustment of the lower limit of the 95% confidence interval above 30% for the primary efficacy endpoint.TRIAL DESIGNThis is a Phase III, randomized, multicenter, endpoint driven, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of the adsorbed vaccine COVID-19 (inactivated) produced by Sinovac. The adsorbed vaccine COVID-19 (inactivated) produced by Sinovac (product under investigation) will be compared to placebo. Voluntary participants will be randomized to receive two intramuscular doses of the investigational product or the placebo, in a 1: 1 ratio, stratified by age group (18 to 59 years and 60 years or more) and will be monitored for one year by active surveillance of COVID-19. Two databases will be established according to the age groups: one for adults (18-59 years) and one for the elderly (60 years of age or older). The threshold to consider the vaccine efficacious will be to reach a protection level of at least 50%, as proposed by the World Health Organization and the FDA. Success in this criterion will be defined by sequential monitoring with adjustment of the lower limit of the 95% confidence interval above 30% for the primary efficacy endpoint.Healthy participants and / or participants with clinically controlled disease, of both genders, 18 years of age or older, working as health professionals performing care in units specialized in direct contact with people with possible or confirmed cases of COVID-19. Participation of pregnant women and those who are breastfeeding, as well as those intending to become pregnant within three months after vaccination will not be allowed. Participants will only be included after signing the voluntary Informed Consent Form and ensuring they undergo screening evaluation and conform to all the inclusion and exclusion criteria. All the clinical sites are located in Brazil.PARTICIPANTSHealthy participants and / or participants with clinically controlled disease, of both genders, 18 years of age or older, working as health professionals performing care in units specialized in direct contact with people with possible or confirmed cases of COVID-19. Participation of pregnant women and those who are breastfeeding, as well as those intending to become pregnant within three months after vaccination will not be allowed. Participants will only be included after signing the voluntary Informed Consent Form and ensuring they undergo screening evaluation and conform to all the inclusion and exclusion criteria. All the clinical sites are located in Brazil.Experimental intervention: The vaccine was manufactured by Sinovac Life Sciences (Beijing, China) and contains 3 μg/0.5 mL (equivalent to 600 SU per dose) of inactivated SARS-CoV-2 virus, and aluminium hydroxide as adjuvant. Control comparator: The placebo contains aluminium hydroxide in a 0.5 mL solution The schedule of both, experimental intervention and placebo is two 0.5 mL doses IM (deltoid) with a two week interval.INTERVENTION AND COMPARATORExperimental intervention: The vaccine was manufactured by Sinovac Life Sciences (Beijing, China) and contains 3 μg/0.5 mL (equivalent to 600 SU per dose) of inactivated SARS-CoV-2 virus, and aluminium hydroxide as adjuvant. Control comparator: The placebo contains aluminium hydroxide in a 0.5 mL solution The schedule of both, experimental intervention and placebo is two 0.5 mL doses IM (deltoid) with a two week interval.The primary efficacy endpoint is the incidence of symptomatic cases of virologically confirmed COVID-19 two weeks after the second vaccination. The virological diagnosis will be confirmed by detection of SARS-CoV-2 nucleic acid in a clinical sample. The primary safety endpoint is the frequency of solicited and unsolicited local and systemic adverse reactions during the period of one week after vaccination according to age group in adult (18-59 years old) and elder (60 years of age or older) subjects. Adverse reactions are defined as adverse events that have a reasonable causal relationship to vaccination.MAIN OUTCOMESThe primary efficacy endpoint is the incidence of symptomatic cases of virologically confirmed COVID-19 two weeks after the second vaccination. The virological diagnosis will be confirmed by detection of SARS-CoV-2 nucleic acid in a clinical sample. The primary safety endpoint is the frequency of solicited and unsolicited local and systemic adverse reactions during the period of one week after vaccination according to age group in adult (18-59 years old) and elder (60 years of age or older) subjects. Adverse reactions are defined as adverse events that have a reasonable causal relationship to vaccination.There will be two randomization lists, one for each age group, based on the investigational products to be administered, i.e., vaccine or placebo at a 1: 1 ratio. Each randomization list will be made to include up to 11,800 (18-59 year-old) adults, and 1,260 elderly (60 y-o and older) participants, the maximum number of participants needed per age group. An electronic central randomization system will be used to designate the investigational product that each participant must receive.RANDOMISATIONThere will be two randomization lists, one for each age group, based on the investigational products to be administered, i.e., vaccine or placebo at a 1: 1 ratio. Each randomization list will be made to include up to 11,800 (18-59 year-old) adults, and 1,260 elderly (60 y-o and older) participants, the maximum number of participants needed per age group. An electronic central randomization system will be used to designate the investigational product that each participant must receive.This trial is designed as a double-blind study to avoid introducing bias in the evaluation of efficacy, safety and immunogenicity. The clinical care team, the professionals responsible for the vaccination and the participants will not know which investigational product will be administered. Only pharmacists or nurses in the study who are responsible for the randomization, separation and blinding of the investigational product will have access to unblinded information. The sponsor's operational team will also remain blind.BLINDING (MASKING)This trial is designed as a double-blind study to avoid introducing bias in the evaluation of efficacy, safety and immunogenicity. The clinical care team, the professionals responsible for the vaccination and the participants will not know which investigational product will be administered. Only pharmacists or nurses in the study who are responsible for the randomization, separation and blinding of the investigational product will have access to unblinded information. The sponsor's operational team will also remain blind.The total number of participants needed to evaluate efficacy, 13,060 participants, satisfies the needed sample size calculated to evaluate safety. Therefore, the total number obtained for efficacy will be the number retained for the study. Up to 13,060 participants are expected to enter the study, with up to 11,800 participants aged 18 to 59 years and 1,260 elderly participants aged 60 and over. Half of the participants of each group will receive the experimental vaccine and half of them will receive the placebo. The recruitment of participants may be modified as recommended by the Data Safety Monitoring Committee at time of the interim unblinded analysis or blind assessment of the COVID-19 attack rate during the study.NUMBERS TO BE RANDOMISED (SAMPLE SIZE)The total number of participants needed to evaluate efficacy, 13,060 participants, satisfies the needed sample size calculated to evaluate safety. Therefore, the total number obtained for efficacy will be the number retain Objectives To evaluate the efficacy of two doses of the adsorbed vaccine COVID-19 (inactivated) produced by Sinovac in symptomatic individuals, with virological confirmation of COVID-19, two weeks after the completion of the two-dose vaccination regimen, aged 18 years or older who work as health professionals providing care to patients with possible or confirmed COVID-19. To describe the occurrence of adverse reactions associated with the administration of each of two doses of the adsorbed vaccine COVID-19 (inactivated) produced by Sinovac up to one week after vaccination in Adults (18-59 years of age) and Elderly (60 years of age or more). Trial design This is a Phase III, randomized, multicenter, endpoint driven, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of the adsorbed vaccine COVID-19 (inactivated) produced by Sinovac. The adsorbed vaccine COVID-19 (inactivated) produced by Sinovac (product under investigation) will be compared to placebo. Voluntary participants will be randomized to receive two intramuscular doses of the investigational product or the placebo, in a 1: 1 ratio, stratified by age group (18 to 59 years and 60 years or more) and will be monitored for one year by active surveillance of COVID-19. Two databases will be established according to the age groups: one for adults (18-59 years) and one for the elderly (60 years of age or older). The threshold to consider the vaccine efficacious will be to reach a protection level of at least 50%, as proposed by the World Health Organization and the FDA. Success in this criterion will be defined by sequential monitoring with adjustment of the lower limit of the 95% confidence interval above 30% for the primary efficacy endpoint. Participants Healthy participants and / or participants with clinically controlled disease, of both genders, 18 years of age or older, working as health professionals performing care in units specialized in direct contact with people with possible or confirmed cases of COVID-19. Participation of pregnant women and those who are breastfeeding, as well as those intending to become pregnant within three months after vaccination will not be allowed. Participants will only be included after signing the voluntary Informed Consent Form and ensuring they undergo screening evaluation and conform to all the inclusion and exclusion criteria. All the clinical sites are located in Brazil. Intervention and comparator Experimental intervention: The vaccine was manufactured by Sinovac Life Sciences (Beijing, China) and contains 3 μg/0.5 mL (equivalent to 600 SU per dose) of inactivated SARS-CoV-2 virus, and aluminium hydroxide as adjuvant. Control comparator: The placebo contains aluminium hydroxide in a 0.5 mL solution The schedule of both, experimental intervention and placebo is two 0.5 mL doses IM (deltoid) with a two week interval. Main outcomes The primary efficacy endpoint is the incidence of symptomatic cases of virologically confirmed COVID-19 two weeks after the second vaccination. The virological diagnosis will be confirmed by detection of SARS-CoV-2 nucleic acid in a clinical sample. The primary safety endpoint is the frequency of solicited and unsolicited local and systemic adverse reactions during the period of one week after vaccination according to age group in adult (18-59 years old) and elder (60 years of age or older) subjects. Adverse reactions are defined as adverse events that have a reasonable causal relationship to vaccination. Randomisation There will be two randomization lists, one for each age group, based on the investigational products to be administered, i.e ., vaccine or placebo at a 1: 1 ratio. Each randomization list will be made to include up to 11,800 (18-59 year-old) adults, and 1,260 elderly (60 y-o and older) participants, the maximum number of participants needed per age group. An electronic central randomization system will be used to designate the investigational product that each participant must receive. Blinding (masking) This trial is designed as a double-blind study to avoid introducing bias in the evaluation of efficacy, safety and immunogenicity. The clinical care team, the professionals responsible for the vaccination and the participants will not know which investigational product will be administered. Only pharmacists or nurses in the study who are responsible for the randomization, separation and blinding of the investigational product will have access to unblinded information. The sponsor's operational team will also remain blind. Numbers to be randomised (sample size) The total number of participants needed to evaluate efficacy, 13,060 participants, satisfies the needed sample size calculated to evaluate safety. Therefore, the total number obtained for efficacy will be the number retained for the study. Up to 13,060 participants are expected to enter the study, with up to 11,800 participants aged 18 to 59 years and 1,260 elderly participants aged 60 and over. Half of the participants of each group will receive the experimental vaccine and half of them will receive the placebo. The recruitment of participants may be modified as recommended by the Data Safety Monitoring Committee at time of the interim unblinded analysis or blind assessment of the COVID-19 attack rate during the study. Trial Status Protocol version 2.0 – 24-Aug-2020. Recruitment started on July 21 st , 2020. The recruitment is expected to conclude in October 2020. Trial registration ClinicalTrials.gov Identifier: NCT0445659 . Registry on 2 July 2020 Full protocol The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1 ). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. Abstract Objectives To evaluate the efficacy of two doses of the adsorbed vaccine COVID-19 (inactivated) produced by Sinovac in symptomatic individuals, with virological confirmation of COVID-19, two weeks after the completion of the two-dose vaccination regimen, aged 18 years or older who work as health professionals providing care to patients with possible or confirmed COVID-19. To describe the occurrence of adverse reactions associated with the administration of each of two doses of the adsorbed vaccine COVID-19 (inactivated) produced by Sinovac up to one week after vaccination in Adults (18-59 years of age) and Elderly (60 years of age or more). Trial design This is a Phase III, randomized, multicenter, endpoint driven, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of the adsorbed vaccine COVID-19 (inactivated) produced by Sinovac. The adsorbed vaccine COVID-19 (inactivated) produced by Sinovac (product under investigation) will be compared to placebo. Voluntary participants will be randomized to receive two intramuscular doses of the investigational product or the placebo, in a 1: 1 ratio, stratified by age group (18 to 59 years and 60 years or more) and will be monitored for one year by active surveillance of COVID-19. Two databases will be established according to the age groups: one for adults (18-59 years) and one for the elderly (60 years of age or older). The threshold to consider the vaccine efficacious will be to reach a protection level of at least 50%, as proposed by the World Health Organization and the FDA. Success in this criterion will be defined by sequential monitoring with adjustment of the lower limit of the 95% confidence interval above 30% for the primary efficacy endpoint. Participants Healthy participants and / or participants with clinically controlled disease, of both genders, 18 years of age or older, working as health professionals performing care in units specialized in direct contact with people with possible or confirmed cases of COVID-19. Participation of pregnant women and those who are breastfeeding, as well as those intending to become pregnant within three months after vaccination will not be allowed. Participants will only be included after signing the voluntary Informed Consent Form and ensuring they undergo screening evaluation and conform to all the inclusion and exclusion criteria. All the clinical sites are located in Brazil. Intervention and comparator Experimental intervention: The vaccine was manufactured by Sinovac Life Sciences (Beijing, China) and contains 3 μg/0.5 mL (equivalent to 600 SU per dose) of inactivated SARS-CoV-2 virus, and aluminium hydroxide as adjuvant. Control comparator: The placebo contains aluminium hydroxide in a 0.5 mL solution The schedule of both, experimental intervention and placebo is two 0.5 mL doses IM (deltoid) with a two week interval. Main outcomes The primary efficacy endpoint is the incidence of symptomatic cases of virologically confirmed COVID-19 two weeks after the second vaccination. The virological diagnosis will be confirmed by detection of SARS-CoV-2 nucleic acid in a clinical sample. The primary safety endpoint is the frequency of solicited and unsolicited local and systemic adverse reactions during the period of one week after vaccination according to age group in adult (18-59 years old) and elder (60 years of age or older) subjects. Adverse reactions are defined as adverse events that have a reasonable causal relationship to vaccination. Randomisation There will be two randomization lists, one for each age group, based on the investigational products to be administered, i.e., vaccine or placebo at a 1: 1 ratio. Each randomization list will be made to include up to 11,800 (18-59 year-old) adults, and 1,260 elderly (60 y-o and older) participants, the maximum number of participants needed per age group. An electronic central randomization system will be used to designate the investigational product that each participant must receive. Blinding (masking) This trial is designed as a double-blind study to avoid introducing bias in the evaluation of efficacy, safety and immunogenicity. The clinical care team, the professionals responsible for the vaccination and the participants will not know which investigational product will be administered. Only pharmacists or nurses in the study who are responsible for the randomization, separation and blinding of the investigational product will have access to unblinded information. The sponsor's operational team will also remain blind. Numbers to be randomised (sample size) The total number of participants needed to evaluate efficacy, 13,060 participants, satisfies the needed sample size calculated to evaluate safety. Therefore, the total number obtained for efficacy will be the number retained for the study. Up to 13,060 participants are expected to enter the study, with up to 11,800 participants aged 18 to 59 years and 1,260 elderly participants aged 60 and over. Half of the participants of each group will receive the experimental vaccine and half of them will receive the placebo. The recruitment of participants may be modified as recommended by the Data Safety Monitoring Committee at time of the interim unblinded analysis or blind assessment of the COVID-19 attack rate during the study. Trial Status Protocol version 2.0 – 24-Aug-2020. Recruitment started on July 21st, 2020. The recruitment is expected to conclude in October 2020. Trial registration ClinicalTrials.gov Identifier: NCT0445659 . Registry on 2 July 2020 Full protocol The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. |
| ArticleNumber | 853 |
| Author | Ockenhouse, Christian F. Xin, Qianqian Kallas, Esper G. Zeng, Gang de Oliveira Piorelli, Roberta Batista, Ana Paula Gast, Christopher Conde, Monica Tilli Reis Pessoa Patiño, Elizabeth González Palacios, Ricardo Flores, Jorge |
| Author_xml | – sequence: 1 givenname: Ricardo orcidid: 0000-0002-1410-8579 surname: Palacios fullname: Palacios, Ricardo email: ricardo.palacios@butantan.gov.br organization: Center for Clinical Trials and Pharmacovigilance, Instituto Butantan – sequence: 2 givenname: Elizabeth González surname: Patiño fullname: Patiño, Elizabeth González organization: Center for Clinical Trials and Pharmacovigilance, Instituto Butantan – sequence: 3 givenname: Roberta surname: de Oliveira Piorelli fullname: de Oliveira Piorelli, Roberta organization: Center for Clinical Trials and Pharmacovigilance, Instituto Butantan – sequence: 4 givenname: Monica Tilli Reis Pessoa surname: Conde fullname: Conde, Monica Tilli Reis Pessoa organization: Center for Clinical Trials and Pharmacovigilance, Instituto Butantan – sequence: 5 givenname: Ana Paula surname: Batista fullname: Batista, Ana Paula organization: Center for Clinical Trials and Pharmacovigilance, Instituto Butantan – sequence: 6 givenname: Gang surname: Zeng fullname: Zeng, Gang organization: Sinovac Life Sciences – sequence: 7 givenname: Qianqian surname: Xin fullname: Xin, Qianqian organization: Sinovac Life Sciences – sequence: 8 givenname: Esper G. surname: Kallas fullname: Kallas, Esper G. organization: Department of Infectious and Parasitic Diseases, School of Medicine, University of São Paulo – sequence: 9 givenname: Jorge surname: Flores fullname: Flores, Jorge organization: PATH US – sequence: 10 givenname: Christian F. surname: Ockenhouse fullname: Ockenhouse, Christian F. organization: PATH US – sequence: 11 givenname: Christopher surname: Gast fullname: Gast, Christopher organization: PATH |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33059771$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9k8tu1DAYhQMqohd4ARbIEpsiEfA1ly6QyrSlkYo6aku3luM4M648drGdQcOKd-ANeRI8My29LLpJrN_nfD6-_NvZhnVWZdkbBD8iVBWfAiKwIDnEMIe0LFlOn2dbqKQsLzBiG_fGm9l2CFcQUlIT-jLbJASyuizR1jN04IbWqPyL0bb7AM6E7dxM_1JpPDZCqtblI2ejd8aoDoynIijQNA0YJb2WwoALr9M3OnA4F2YQUYE4VeCw79OsXIDEA-eiV3EBXA-iVyJqOwHHSpg4lcIrMPauVyFoZ4UJ4KeO0xVhvwvOt2nN0ellc5CjGuw2Vsio52mN7j24FFJqq8A3YYc-1QeftO0CnGvr5kKCv7__gPHZ6VFzngB7YB-E6IcbWRhmM-FXiUSqD90CXHsXnXQG9M6nol-fQ0hiebf9uNzrq-xFn5Kq1zf_nez70eHF6Dg_Of3ajPZPcskojHndt4q1mBGIsezqsurKAiJWtkzgqqtI2ypc0qJDLe4gbGUPSd1TnDxKdZgJspM1a27nxBW_9noZmTuh-arg_IQLH7U0ipdFWxOoKkxLmZBYFIwgKSmSlEhEcGJ9XrOuh3amOqnSloR5AH04Y_WUT9ycl4xVmC0BuzcA734MKkSeDkcqY4RVbggcU4YqWtUVS9J3j6RXbvDLy-W4QpjgAmGYVG_vJ_of5fZlJkG1FkjvQvCq51LH9HiWtyG04QjyZRPwdRPw1AR81QScJit-ZL2lP2kia1NIYjtR_i72E65_uTEdmw |
| CitedBy_id | crossref_primary_10_1177_0976500X221138393 crossref_primary_10_1016_j_intimp_2021_108021 crossref_primary_10_1186_s40001_023_01210_7 crossref_primary_10_1016_j_micinf_2021_104841 crossref_primary_10_1016_j_ijregi_2023_04_003 crossref_primary_10_1038_s41580_021_00418_x crossref_primary_10_1097_CM9_0000000000002767 crossref_primary_10_7774_cevr_2023_12_3_224 crossref_primary_10_3389_fimmu_2021_708848 crossref_primary_10_12998_wjcc_v9_i27_8274 crossref_primary_10_1038_s41590_024_01944_4 crossref_primary_10_3389_fcimb_2021_720357 crossref_primary_10_1016_j_jad_2022_08_080 crossref_primary_10_3389_fpubh_2022_1033473 crossref_primary_10_1016_j_heliyon_2024_e30087 crossref_primary_10_1186_s40779_021_00360_1 crossref_primary_10_1002_jcla_24418 crossref_primary_10_1017_ice_2021_365 crossref_primary_10_1590_0037_8682_0152_2023 crossref_primary_10_1080_22221751_2021_1969291 crossref_primary_10_1038_s41598_025_94596_9 crossref_primary_10_1186_s12879_022_07452_w crossref_primary_10_1590_1806_9282_20210755 crossref_primary_10_1080_14760584_2021_1925112 crossref_primary_10_1002_gch2_202100004 crossref_primary_10_1016_j_vaccine_2025_127559 crossref_primary_10_3389_fimmu_2022_836232 crossref_primary_10_1186_s12985_022_01935_7 crossref_primary_10_3390_biom13111565 crossref_primary_10_1016_j_ijid_2021_12_316 crossref_primary_10_1186_s12951_022_01625_0 crossref_primary_10_3389_fimmu_2021_766278 crossref_primary_10_3390_vaccines10040539 crossref_primary_10_3390_vaccines9050524 crossref_primary_10_15829_1728_8800_2023_3820 crossref_primary_10_4103_2045_9912_326003 crossref_primary_10_1080_07391102_2021_1973563 crossref_primary_10_1016_j_intimp_2021_107622 crossref_primary_10_3390_cells10040821 crossref_primary_10_1016_j_medcle_2021_05_003 crossref_primary_10_1016_j_addr_2020_12_006 crossref_primary_10_3390_vaccines10040495 crossref_primary_10_12688_f1000research_52216_1 crossref_primary_10_4103_ijpvm_ijpvm_27_21 crossref_primary_10_1038_s41562_021_01155_z crossref_primary_10_3389_fimmu_2022_947602 crossref_primary_10_3390_vaccines11010080 crossref_primary_10_1016_S2665_9913_22_00130_8 crossref_primary_10_1038_s41392_021_00733_x crossref_primary_10_3389_fcimb_2021_821828 crossref_primary_10_1007_s11033_022_07308_1 crossref_primary_10_1016_j_jad_2021_10_088 crossref_primary_10_1080_14737159_2021_1917998 crossref_primary_10_3390_microorganisms9040793 crossref_primary_10_1093_femsre_fuab035 crossref_primary_10_1080_21645515_2022_2146964 crossref_primary_10_3390_vaccines11020442 crossref_primary_10_1186_s43162_024_00369_7 crossref_primary_10_1097_SLA_0000000000005176 crossref_primary_10_3390_vaccines12020130 crossref_primary_10_1080_14760584_2022_2016400 crossref_primary_10_3389_fimmu_2022_1032411 crossref_primary_10_1007_s00109_020_02012_8 crossref_primary_10_1016_j_ijid_2021_11_009 crossref_primary_10_1016_j_heliyon_2022_e12594 crossref_primary_10_1016_j_ijid_2021_01_035 crossref_primary_10_1016_j_ijid_2024_107149 crossref_primary_10_1039_D0RA09668G crossref_primary_10_3389_fimmu_2023_1122651 crossref_primary_10_1128_msystems_00927_22 crossref_primary_10_2147_IJGM_S422337 crossref_primary_10_1080_21645515_2022_2087412 crossref_primary_10_4254_wjh_v13_i12_1850 crossref_primary_10_3390_vaccines11081329 crossref_primary_10_1007_s11684_021_0913_y crossref_primary_10_1007_s40744_022_00462_9 crossref_primary_10_1093_ajcp_aqab107 crossref_primary_10_3390_vaccines10081229 crossref_primary_10_3201_eid2712_211772 crossref_primary_10_1186_s12889_023_15596_w crossref_primary_10_3389_fpubh_2023_1115127 crossref_primary_10_1002_ueg2_12103 crossref_primary_10_1007_s42770_024_01600_x crossref_primary_10_3390_vaccines9010030 crossref_primary_10_3390_vaccines10122086 crossref_primary_10_1186_s12879_022_07449_5 crossref_primary_10_3390_v15112181 crossref_primary_10_1093_oxfimm_iqab010 crossref_primary_10_1080_21645515_2022_2135929 crossref_primary_10_1016_j_vaccine_2023_06_017 crossref_primary_10_3390_cells10071756 crossref_primary_10_3390_vaccines10060878 crossref_primary_10_3390_ijerph20031756 crossref_primary_10_1007_s40199_022_00446_8 crossref_primary_10_1016_j_jafr_2024_101029 crossref_primary_10_1089_blr_2025_80807_nl crossref_primary_10_1093_cid_ciaa1911 crossref_primary_10_3389_fimmu_2025_1603612 crossref_primary_10_3390_ijms23158485 crossref_primary_10_1038_s41467_024_50802_2 crossref_primary_10_36233_0507_4088_303 crossref_primary_10_1371_journal_pgph_0004069 crossref_primary_10_1038_s41541_025_01211_z crossref_primary_10_1016_j_ijid_2021_09_060 crossref_primary_10_3390_v15020530 crossref_primary_10_3390_vaccines10111855 crossref_primary_10_1126_scitranslmed_abn9243 crossref_primary_10_3390_vaccines10040608 crossref_primary_10_1177_0890334421995102 crossref_primary_10_1007_s11101_021_09759_z crossref_primary_10_1111_jocd_15209 crossref_primary_10_1136_bmj_n299 crossref_primary_10_3389_fcimb_2024_1371695 crossref_primary_10_3390_v16020203 crossref_primary_10_1016_j_virs_2022_05_006 crossref_primary_10_1097_WNO_0000000000001537 crossref_primary_10_1016_j_intimp_2021_108162 crossref_primary_10_1186_s40794_021_00159_x crossref_primary_10_3389_fcimb_2024_1345683 crossref_primary_10_1016_j_medcli_2021_05_008 crossref_primary_10_3390_vaccines9010011 crossref_primary_10_3350_cmh_2022_0087 crossref_primary_10_1097_EDE_0000000000001473 crossref_primary_10_1155_2023_1879554 crossref_primary_10_1017_dmp_2024_331 crossref_primary_10_1016_j_ijid_2022_08_026 crossref_primary_10_1590_0037_8682_0385_2021 crossref_primary_10_1016_j_vaccine_2021_11_091 crossref_primary_10_3390_vaccines10060853 crossref_primary_10_1186_s13023_024_03260_4 crossref_primary_10_1007_s11096_021_01344_w crossref_primary_10_1016_j_autrev_2023_103508 crossref_primary_10_1016_j_vaccine_2022_10_017 crossref_primary_10_1016_j_crmeth_2022_100181 crossref_primary_10_1016_j_lansea_2022_100121 crossref_primary_10_3389_fcimb_2021_690621 crossref_primary_10_1016_j_jaip_2021_07_016 crossref_primary_10_1136_bmjopen_2021_057024 crossref_primary_10_3389_fimmu_2021_635471 crossref_primary_10_3389_fpubh_2024_1179268 crossref_primary_10_3389_fimmu_2024_1298471 crossref_primary_10_3390_vaccines12121367 crossref_primary_10_1016_j_jinf_2024_106315 crossref_primary_10_1038_s41541_021_00393_6 crossref_primary_10_4274_tjps_galenos_2023_50880 crossref_primary_10_3390_ijms24054398 crossref_primary_10_5858_arpa_2023_0370_OA crossref_primary_10_1002_jmv_28172 crossref_primary_10_3389_fimmu_2022_938378 crossref_primary_10_3390_v13030418 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2020 The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2020 – notice: The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU COVID DWQXO FYUFA GHDGH K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s13063-020-04775-4 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central - New (Subscription) ProQuest One Coronavirus Research Database ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni Edition) Medical Database ProQuest Nursing and Allied Health Premium ProQuest Central Premium ProQuest One Academic Publicly Available Content Database (subscription) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Publicly Available Content Database MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1745-6215 |
| EndPage | 3 |
| ExternalDocumentID | oai_doaj_org_article_76b930e8247c46d2a6531cc41c43c132 PMC7558252 33059771 10_1186_s13063_020_04775_4 |
| Genre | Letter Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial Correspondence |
| GeographicLocations | Brazil |
| GeographicLocations_xml | – name: Brazil |
| GrantInformation_xml | – fundername: Fundação de Amparo à Pesquisa do Estado de São Paulo grantid: 2020/10127-1 funderid: http://dx.doi.org/10.13039/501100001807 – fundername: Fundação Butantan funderid: http://dx.doi.org/10.13039/501100005942 – fundername: Fundação de Amparo à Pesquisa do Estado de São Paulo grantid: 2020/10127-1 – fundername: ; – fundername: ; grantid: 2020/10127-1 |
| GroupedDBID | --- 0R~ 123 2-G 29Q 2WC 53G 5VS 6PF 7RV 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACUHS ADBBV ADRAZ ADUKV AEGXH AENEX AFKRA AFPKN AHBYD AHYZX AIAGR ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC C6C CCPQU CS3 DIK DU5 E3Z EBD EBLON EBS EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E NAPCQ O5R O5S OVT PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS U2A UKHRP WOQ WOW ~8M AAYXX AFFHD CITATION -5E -5G -A0 -BR ACRMQ ADINQ ALIPV C24 CGR CUY CVF ECM EIF NPM 3V. 5GY 7XB 8FK AHMBA AZQEC COVID DWQXO K9. PKEHL PQEST PQQKQ PQUKI PRINS XSB 7X8 5PM |
| ID | FETCH-LOGICAL-c540t-9fbe5b253022cd978d760157b5a28d83bbe2746d1b2d00bcf039f42e5beed25a3 |
| IEDL.DBID | RSV |
| ISICitedReferencesCount | 179 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000581650900001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1745-6215 |
| IngestDate | Mon Nov 10 04:32:32 EST 2025 Tue Nov 04 02:05:46 EST 2025 Wed Oct 01 12:33:37 EDT 2025 Sun Oct 19 01:35:43 EDT 2025 Thu Jan 02 22:54:35 EST 2025 Sat Nov 29 06:09:43 EST 2025 Tue Nov 18 22:14:40 EST 2025 Sat Sep 06 07:26:43 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | COVID-19 COVID-19 Vaccine protocol Phase III Clinical Trial Randomised controlled trial Brazil Inactivated Vaccines |
| Language | English |
| License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c540t-9fbe5b253022cd978d760157b5a28d83bbe2746d1b2d00bcf039f42e5beed25a3 |
| Notes | SourceType-Scholarly Journals-1 ObjectType-Correspondence-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 ObjectType-Correspondence-3 content type line 23 ObjectType-Undefined-4 |
| ORCID | 0000-0002-1410-8579 |
| OpenAccessLink | https://link.springer.com/10.1186/s13063-020-04775-4 |
| PMID | 33059771 |
| PQID | 2812326120 |
| PQPubID | 44365 |
| PageCount | 3 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_76b930e8247c46d2a6531cc41c43c132 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7558252 proquest_miscellaneous_2451848985 proquest_journals_2812326120 pubmed_primary_33059771 crossref_citationtrail_10_1186_s13063_020_04775_4 crossref_primary_10_1186_s13063_020_04775_4 springer_journals_10_1186_s13063_020_04775_4 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-10-15 |
| PublicationDateYYYYMMDD | 2020-10-15 |
| PublicationDate_xml | – month: 10 year: 2020 text: 2020-10-15 day: 15 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Current controlled trials in cardiovascular medicine |
| PublicationTitleAbbrev | Trials |
| PublicationTitleAlternate | Trials |
| PublicationYear | 2020 |
| Publisher | BioMed Central Springer Nature B.V BMC |
| Publisher_xml | – name: BioMed Central – name: Springer Nature B.V – name: BMC |
| SSID | ssj0043934 ssj0017864 |
| Score | 2.625659 |
| Snippet | Objectives
To evaluate the efficacy of two doses of the adsorbed vaccine COVID-19 (inactivated) produced by Sinovac in symptomatic individuals, with... To evaluate the efficacy of two doses of the adsorbed vaccine COVID-19 (inactivated) produced by Sinovac in symptomatic individuals, with virological... ObjectivesTo evaluate the efficacy of two doses of the adsorbed vaccine COVID-19 (inactivated) produced by Sinovac in symptomatic individuals, with virological... Abstract Objectives To evaluate the efficacy of two doses of the adsorbed vaccine COVID-19 (inactivated) produced by Sinovac in symptomatic individuals, with... |
| SourceID | doaj pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 853 |
| SubjectTerms | Adolescent Adult Age groups Aged Betacoronavirus - genetics Betacoronavirus - immunology Biomedicine Brazil - epidemiology Case-Control Studies Clinical trials Coronavirus Infections - epidemiology Coronavirus Infections - immunology Coronavirus Infections - prevention & control Coronavirus Infections - virology Coronaviruses COVID-19 COVID-19 study protocols COVID-19 Vaccine COVID-19 vaccines Data Management Double-Blind Method Female Health Personnel - statistics & numerical data Health Sciences Humans Immunization Inactivated Vaccines Incidence Informed Consent - ethics Injections, Intramuscular Letter Male Medical personnel Medicine Medicine & Public Health Middle Aged Pandemics - prevention & control Phase III Clinical Trial Placebos - administration & dosage Pneumonia, Viral - epidemiology Pneumonia, Viral - immunology Pneumonia, Viral - prevention & control Pneumonia, Viral - virology protocol Randomised controlled trial Safety SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Statistics for Life Sciences Therapies, Investigational - methods Treatment Outcome Vaccination - methods Vaccines - administration & dosage Vaccines - adverse effects Vaccines - therapeutic use Young Adult |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9NAEF5QhRAXxLuGggaJA4ha9WvtXW5pSFRLtI2aUvVm7ctqpGCjOKkUTvwH_iG_hNm1kzY8L9wie7yenczMznhnvyHklQiykqPb97lmqZ-UaFKsxD8kpqkUIZdh6fqnnH3Ijo7Y-TkfXWv1ZWvCWnjgVnB7WSp5HBgWJZlKUh2JFLVGqSRUSawwlbLeN8j4KplqfTCusnGyOiLD0r0GPbXbr7SljFlG_WRjGXJo_b8LMX-tlPxpu9StQsN75G4XPkKvZfs-uWmqB-T2YbdB_vBGiAGxnBp_H6NHvQsnotL1p8kXg79H9oO5rP1-W5w-NRpGF7iGQZ7n0MGDTuHUKiTMaxi0MOAGMEKEgQWaEGoJOB6MRWnmS6hLcFXqyCccrKvIYHQN66MB-5nXjdDTTT2T-M7-8Vn-3g85vM4re6jiEt-h38CZUHYGcCiqhT1ssZghrVzCeGK7tir4_vUbjE6Oh_kYB3gHPWiBbx1ZdwDPciTA4eWChZ-oUccBY3K8OGvl0CCxupq-61jyiHwcDk77B37XFcJXGF3OfV5KQ2Vkux1FSmMSrG1ZD80kFRHTLJbSYKad6lBGOgikKoOYl0mEz2A4EFERPyZbVV2ZbQI81pTJrDRlIBJDuYxxghmGOFIlUmvpkXClJIXqINNt545p4VInlhatYhWoWIVTrCLxyNv1M59bwJC_Uu9b3VtTWrBvdwFNoOhMoPiXCXhkZ6W5ReeBmiJiNljG-DXwyMv1bZS03RASlakXSJNQTPAZZ9QjT1pFX3MS40KAuUHokWzDBDZY3bxTTS4cPnlGKYsosrW7MpYrtv4siqf_QxTPyJ3IWrktOaI7ZAtV0Twnt9TlfNLMXjgf8QOgKWxe priority: 102 providerName: Directory of Open Access Journals – databaseName: Nursing & Allied Health Database dbid: 7RV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9NAEF6gIMSFZ4FAQYPEAUSt-rXeNReUhkaNRNuoKVFv1r5MIwW7xEmlcOI_8A_5JcyunYTw6IWbZY_XO-vZmdmd2W8IeSl8lqeo9r1U88SLc5xSPMcfEtFEiiCVQe7qpww_sMNDfnqa9psNt6pJq1zoRKeodansHvlOyK3xR3vsvzv_4tmqUTa62pTQuEauB9Y3Rnlmx8NlFIHxJF4clOHJToX62kUtbUIjY9SL14yRw-z_m6P5Z77kb0FTZ4u6d_6Xi7vkduOFQrsWm3vkqinuk5sHTZz9wZUA_Wo5Nt4uOqF6G45FocvPo68Gr_t2312WXqfOcR8bDf0zNIXQ6_WgQRkdw4mVa5iWsFejiRtARxP2LF6FUHPA9mAgcjOdQ5mDS3ZHRmF_mYwG_V8gQyqwu8WuhbauyonEb3aOhr33XpDCq15hz2Zc4Df0axgKZTmAA1HM7JmN2QRp5RwGI1v8VcGPb9-hf3zU7Q2wgbfQhho_15E15_hsjwQ42F2wKBYlThVA1x5vTupxqJBYrdh3hU82ycfu3kln32uKS3gKndSpl-bSUBnaokmh0riW1jY7iDJJRcg1j6Q0uGBPdCBD7ftS5X6U5nGI76BXEVIRPSQbRVmYxwTSSFMuWW5yX8SGpjJCBhl6SlLFUmvZIsFCyjLVIK_bAiDjzK3AeJLVkpmhZGZOMrO4Rd4s3zmvcUcupd61wruktJjh7kY5-ZQ1KihjiUwj3_AwZgoZC0WC-lepOFBxpIIobJGthcxmjSKrspXAtsiL5WMcaRtXEoUpZ0gT04DHPOW0RR7VM2XZkwjtCS4xghZha3NoravrT4rRmYM5Z5TykGK3thezbdWtfw_Fk8u5eEpuhVYB2JwkukU2UMjMM3JDXUxH1eS5Ux8_ATqSe4U priority: 102 providerName: ProQuest |
| Title | Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac – PROFISCOV: A structured summary of a study protocol for a randomised controlled trial |
| URI | https://link.springer.com/article/10.1186/s13063-020-04775-4 https://www.ncbi.nlm.nih.gov/pubmed/33059771 https://www.proquest.com/docview/2812326120 https://www.proquest.com/docview/2451848985 https://pubmed.ncbi.nlm.nih.gov/PMC7558252 https://doaj.org/article/76b930e8247c46d2a6531cc41c43c132 |
| Volume | 21 |
| WOSCitedRecordID | wos000581650900001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: Open Access: BioMedCentral Open Access Titles customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: RBZ dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: DOA dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: M~E dateStart: 20060101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: 7X7 dateStart: 20000401 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: 7RV dateStart: 20000401 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: BENPR dateStart: 20000401 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database (subscription) customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: PIMPY dateStart: 20000401 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: Springer Journals customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: RSV dateStart: 20000401 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwEDdsQ4gXvj8KozokHkAsIl9OHN620WmR2Ba1oypPkb_CKpUENd2k8cT_wH_IX8LZSToKAwleojQ5O2f37ny2z78j5Dl34yJBs-8kikVOWKBKsQL_kIBGgnuJ8AqbP2X8Lj48ZJNJkrWHwuou2r3bkrSW2qo1i17XaG3tnqMJR4xj6oRrZAOHO2YSNgxH487-4ggbhN3xmEvLrQxBFqn_Mvfy9yjJX7ZK7Qi0d-v_eL9NbrYeJ2w3InKHXNXlXXL9oN1Tv3fFQx9azLSzgxWrLRjyUlWfpl803mdmjV1Uzm4Tzz7TCrITHPYgTVNoEUVncGxkGBYVDBrkcA3oVMLAYFNweQ5YH4x4oRfnUBVgA9uRddhfBp5B9hM8SA1mZdjWsK3qai7wm7tH4_St4yXwIi3NOYwz_IZ6CWMuTQvggJen5nzG6RxpxTmMpibRq4TvX79BNjzaS0dYwRvYhgYr15K1Z_YMRxwsxC4YxIoK1QLQjceH86YfaiSWF823SU7uk_d7g-PdfadNJOFIdEgXTlIITYVvEiT5UuG8WZlIIBoLyn2mWCCExsl5pDzhK9cVsnCDpAh9LIMehE958ICsl1WpHxFIAkWZiAtduDzUNBEBNjBGr0jIUCglesTrZCuXLcq6SfYxy-1si0V5Iws5ykJuZSEPe-TVssznBmPkr9Q7RmSXlAYf3D6o5h_z1tzkcSSSwNXMD2OJDfN5hLZWytCTYSC9wO-RzU7g89Zo1bnPjH-NLq_bI8-Wr7GnzR4SL3V1ijQh9VjIEkZ75GGjH0tOAhw7cDrh9Ui8ojkrrK6-KacnFtI8ppT5FNna6vTngq0_d8XjfyN_Qm74RgVNPBLdJOsodPopuSbPFtN63idr8XBsrpPYXlmfbOwMDrNh367T4K8sPcg-9K2x-QHtoHir |
| linkProvider | Springer Nature |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3JbtRAEG1CQMCFfRkIUEggBRErdnvpNhJCWRUr2ygJUW7GvZiMNNhhPAkaTvwD_8FH8SVUt-0Jw5JbDtwsu9yuXl4t7uoqQp5nLstjFPtOrHjkBDlCiuc4IX4YicyLhZfb-in7G2xrix8cxN0p8r09C2PCKluZaAW1KqX5Rz5PuVH-qI_dt0efHFM1yuyutiU06mWxrkef0WWr3iTLOL8vKF1d2Vtac5qqAo5E62ToxLnQoaCmWg6VCp0oZcJCQibCjHLFfSE0emqR8gRVritk7vpxHlB8B9UJDTMf271ILqEcZ8bZYwdjB89jPAragzk8mq9QP9hdUhNAyVjoBBPKz9YI-Jth-2d85m-btFb3rd7430btJrneWNmwUMPiFpnSxW1yZbOJI7hzwUO_QfS1s4hGtpqDnaxQ5cfeF43XXbOvIEpnqY7h72sF3UNU9ZAkCTRZVPuwZ3ALwxJW6mzpGtCQhhWTjyOTI8D2YDfL9XAEZQ42mB8HFtbGwXbQ_SUlSgXmb7htYUFV5UDgN5e295Nlx4thNinM2ZMT_IZ6CfuZND2Azaw4NmdSjgdIK0aw2zPFbSX8-PoNujvbq8kuNvAaFqDOD2zJmnOKhqMMbFphMFk6ShQFgK4L3hzU41AhsTztvi3scpe8O5cJu0emi7LQDwjEvgq5YLnO3SzQYSx87CBDS1DIQCglOsRrV3Uqm8zypsBJP7UeJo_SGgkpIiG1SEiDDnk1fueozqtyJvWiAcuY0uREtzfKwYe0EbEpi0Tsu5rTgEnsGM0i1C9SBp4MfOn5tENmWoykjaCu0lOAdMiz8WMcabNvlhW6PEaaIPR4wGMedsj9GpljTnzUlygIvA5hE5idYHXySdE7tGncWRhyGiJbcy26T9n691A8PLsXT8nVtb3NjXQj2Vp_RK5RI3xM_FU4Q6ZxwenH5LI8GfaqwRMruoC8P2_U_wQCBtjg |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3JbtRAEG1CgiIu7MtAgEICiYhYsdtbGwmhbKNY2awkROFk3IvJSIMdxpOg4cQ_8Dd8Dl9CddueMCy55cDNssvt3l4truoqQp5ldphHyPatSLLA8nKEFMtxQVw_4JkTcSc39VMONsPtbXZ4GCVT5Ht7FkaHVbY80TBqWQr9j3yRMi38UR7bi3kTFpGsdt8cf7J0BSntaW3LadRbZEONPqP5Vr2OV3Gtn1PaXdtfWbeaCgOWQE1laEU5Vz6nunIOFRINKqlDRPyQ-xllkrmcK7TaAulwKm2bi9x2o9yj-A6KFupnLrZ7mcygSu7RaTKTxFvJu7EPI2SB1x7TYcFihdLC-Ex1OGUY-pY3IQpNxYC_qbl_Rmv-5rI1krB7_X-ewxvkWqN_w1INmJtkShW3yOxWE2Fw-5KDFgXvK2sZ1W-5ALtZIcuPvS8KrxPtceCltVJH9_eVhOQIlQCI4xia_Kp92NeIhmEJa3UedQWoYsOaztSRiRFge7CX5Wo4gjIHE-aPkwzr4zA8SH5JllKB_k9uWliSVTng-M2VnYN41XIieBEX-lTKKX5DzsNBJvQIYCsrTvRplZMB0vIR7PV02VsBP75-g2R3pxvvYQOvYAnqzMGGrDnBqHuUgUk4DDp_R4lMAtCowZuDeh4qJBZnwzclX-6QtxeyYHfJdFEW6j6ByJU-42GucjvzlB9xFwcYoo7Ihcel5B3itDs8FU3OeV36pJ8a25MFaY2KFFGRGlSkXoe8HL9zXGdcOZd6WQNnTKmzpZsb5eBD2jDfNAx45NqKUS8UODCaBSh5hPAc4bnCcWmHzLV4SRsWXqVnYOmQp-PHONPao5YVqjxBGs93mMci5nfIvRql4564KEnRuHI6JJzA70RXJ58UvSOT4D30fUZ97NZCi_Szbv17Kh6cP4onZBbBnm7G2xsPyVWq-ZAOzPLnyDTuN_WIXBGnw141eNzwMSDvLxr2PwHORuMv |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Double-Blind%2C+Randomized%2C+Placebo-Controlled+Phase+III+Clinical+Trial+to+Evaluate+the+Efficacy+and+Safety+of+treating+Healthcare+Professionals+with+the+Adsorbed+COVID-19+%28Inactivated%29+Vaccine+Manufactured+by+Sinovac+-+PROFISCOV%3A+A+structured+summary+of+a+study+protocol+for+a+randomised+controlled+trial&rft.jtitle=Trials&rft.au=Palacios%2C+Ricardo&rft.au=Pati%C3%B1o%2C+Elizabeth+Gonz%C3%A1lez&rft.au=de+Oliveira+Piorelli%2C+Roberta&rft.au=Conde%2C+Monica+Tilli+Reis+Pessoa&rft.date=2020-10-15&rft.eissn=1745-6215&rft.volume=21&rft.issue=1&rft.spage=853&rft_id=info:doi/10.1186%2Fs13063-020-04775-4&rft_id=info%3Apmid%2F33059771&rft.externalDocID=33059771 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1745-6215&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1745-6215&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1745-6215&client=summon |